Biodegradation of 2-fluorobenzoate in upflow fixed bed bioreactors operated with different growth support materials

Three upflow fixed bed bioreactors treating an aqueous stream containing 2-fluorobenzoate were operated for a period of 7months, during which they were exposed to high organic loading rates and starvation. The reactors contained granular activated carbon (GAC), polyethylene (PE) particles and expanded clay (EC) respectively as growth support for microbial biofilms. The performance of the reactors was compared and the biofilm microbial population was followed by cell counting and denaturing gradient gel electrophoresis (DGGE). The reactor containing GAC always had 100% removal efficiency owing to the adsorption properties of thematerial combined with biodegradation. The GAC reactor also recovered better after starvation periods in the sense that it showed more stable behaviour than the reactors containing EC and PE. The highest biological elimination capacity was observed for the reactor containing EC, which reached 200mg day−1 L−1 during reactor start-up, but during long-termoperation the reactor containing GAC showed the highest biological elimination capacity, 140mg day−1 L−1. DGGE analysis indicated that starvation periods seemed to be responsible for shifts in the microbial population

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

Two single nucleotide polymorphisms (SNPs) at 6q25.1, near the ESR1 gene, have been implicated in the susceptibility to breast cancer for Asian (rs2046210) and European women (rs9397435). A genome-wide association study in Europeans identified two further breast cancer susceptibility variants: rs11249433 at 1p11.2 and rs999737 in RAD51L1 at 14q24.1. Although previously identified breast cancer susceptibility variants have been shown to be associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers, the involvement of these SNPs to breast cancer susceptibility in mutation carriers is currently unknown. To address this, we genotyped these SNPs in BRCA1 and BRCA2 mutation carriers from 42 studies from the Consortium of Investigators of Modifiers of BRCA1/2. In the analysis of 14 123 BRCA1 and 8053 BRCA2 mutation carriers of European ancestry, the 6q25.1 SNPs (r2= 0.14) were independently associated with the risk of breast cancer for BRCA1 mutation carriers [hazard ratio (HR) = 1.17, 95% confidence interval (CI): 1.11-1.23, P-trend = 4.5 × 10-9for rs2046210; HR = 1.28, 95% CI: 1.18-1.40, P-trend = 1.3 × 10-8for rs9397435], but only rs9397435 was associated with the risk for BRCA2 carriers (HR = 1.14, 95% CI: 1.01-1.28, P-trend = 0.031). SNP rs11249433 (1p11.2) was associated with the risk of breast cancer for BRCA2 mutation carriers (HR = 1.09, 95% CI: 1.02-1.17, P-trend = 0.015), but was not associated with breast cancer risk for BRCA1 mutation carriers (HR = 0.97, 95% CI: 0.92-1.02, P-trend = 0.20). SNP rs999737 (RAD51L1) was not associated with breast cancer risk for either BRCA1 or BRCA2 mutation carriers (P-trend = 0.27 and 0.30, respectively). The identification of SNPs at 6q25.1 associated with breast cancer risk for BRCA1 mutation carriers will lead to a better understanding of the biology of tumour development in these women